Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of … Read more
Gwo Xi Stem Cell Applied Technology Co. , Ltd - Asset Resilience Ratio
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) has an Asset Resilience Ratio of 2.96% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Gwo Xi Stem Cell Applied Technology Co. , Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Gwo Xi Stem Cell Applied Technology Co. , Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$30.00 Million | 2.96% |
| Total Liquid Assets | NT$30.00 Million | 2.96% |
Asset Resilience Insights
- Limited Liquidity: Gwo Xi Stem Cell Applied Technology Co. , Ltd maintains only 2.96% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gwo Xi Stem Cell Applied Technology Co. , Ltd Industry Peers by Asset Resilience Ratio
Compare Gwo Xi Stem Cell Applied Technology Co. , Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Gwo Xi Stem Cell Applied Technology Co. , Ltd (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Gwo Xi Stem Cell Applied Technology Co. , Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.66% | NT$49.50 Million | NT$1.06 Billion | -0.19pp |
| 2023-12-31 | 4.85% | NT$59.50 Million | NT$1.23 Billion | -- |